ClearPoint NeuroCLPT
CLPT
About: ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
Employees: 115
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
904% more call options, than puts
Call options by funds: $3.65M | Put options by funds: $364K
109% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 11
13% more funds holding
Funds holding: 89 [Q4 2024] → 101 (+12) [Q1 2025]
2.09% more ownership
Funds ownership: 27.56% [Q4 2024] → 29.65% (+2.09%) [Q1 2025]
6% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 31
17% less capital invested
Capital invested by funds: $117M [Q4 2024] → $97.5M (-$19.5M) [Q1 2025]
100% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 0 (-2) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$28
146%
upside
Avg. target
$28
146%
upside
High target
$28
146%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
B. Riley Securities Neil Chatterji | 146%upside $28 | Buy Maintained | 25 Apr 2025 |
Financial journalist opinion
Neutral
24/7 Wall Street
1 day ago
Move Over, Magnificent 7: The Frontier 7 Will Redefine Our Future
Key Points in This Article: The Magnificent 7 transformed markets through AI and digital ecosystems, turning a once-pejorative label into a celebrated symbol of innovation and growth.
Positive
Seeking Alpha
2 weeks ago
ClearPoint Neuro: Consumables Growth Is Promising
ClearPoint's fundamentals remain strong, despite recent stock weakness. Consumables growth and an expectation of 15-20 system placements in 2025 are illustrative of this strength. The introduction of GLP capabilities and the commercialization of partner programs should lead to stronger growth, beginning in late 2025.
Positive
Seeking Alpha
1 month ago
I Missed The Quantum Rally - I Won't Miss The Next One
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.
Positive
Zacks Investment Research
1 month ago
5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS.
Neutral
Seeking Alpha
1 month ago
ClearPoint Neuro, Inc. (CLPT) Q1 2025 Earnings Call Transcript
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Joseph Burnett - President and Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Frank Takkinen - Lake Street Capital Markets Anderson Schock - B. Riley Securities Operator Greetings and welcome to ClearPoint Neuro, Inc. First Quarter 2025 Financial Results Conference Call.
Negative
Zacks Investment Research
1 month ago
ClearPoint Neuro, Inc. (CLPT) Reports Q1 Loss, Tops Revenue Estimates
ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.16 per share a year ago.
Neutral
Accesswire
1 month ago
ClearPoint Neuro Reports First Quarter 2025 Results
Record Revenue Highlighted by 70% Growth in Single-Use Navigation and Therapy Products SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 13, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2025. First Quarter Highlights Reported record quarterly revenue of $8.5 million, an 11% year-over-year increase compared with the first quarter of 2024; Grew total consumable product revenue by $2.6 million year-over-year, or 104%, including biologics and drug delivery cannulas, SmartFrame® Family Navigation devices, and ClearPoint PRISM® Laser Therapy Applicators; Received FDA Clearance for the ClearPoint 3.0 Software which includes both operating room navigation capability and enhanced laser therapy features.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Believe ClearPoint Neuro (CLPT) Could Rally 102.86%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 102.9% in ClearPoint Neuro (CLPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
Accesswire
1 month ago
ClearPoint Neuro Announces Investment of up to $110 Million by Oberland Capital with $33.5 Million Funded at Closing
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / May 12, 2025 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it has entered into a note financing arrangement with Oberland Capital Management LLC ("Oberland Capital") of up to $105 Million, with $30.0 million of gross proceeds funded at closing. Additional note financing will be provided to the Company by Oberland Capital under the following terms: An additional $25.0 million at the option of the Company any time prior to December 31, 2026; and An additional $50.0 million at the option of the Company and Oberland Capital any time prior to December 31, 2026.
Positive
Seeking Alpha
2 months ago
ClearPoint Neuro: Fundamentals Continue To Strengthen
ClearPoint continues to make progress in relation to its LITT and operating room expansion efforts. More importantly, ClearPoint's partners continue to provide positive news in relation to their therapeutic candidates. It will take time for these tailwinds to impact ClearPoint's financials, but 2026/2027 onwards should see a step change in performance.
Charts implemented using Lightweight Charts™